

# Fabiola Moretti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3684231/publications.pdf>

Version: 2024-02-01

59  
papers

1,832  
citations

279798

23  
h-index

276875

41  
g-index

61  
all docs

61  
docs citations

61  
times ranked

2830  
citing authors

#	ARTICLE	IF	CITATIONS
1	HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression. <i>Molecular Cancer Research</i> , 2022, 20, 686-698.	3.4	5
2	Early Social Enrichment Modulates Tumor Progression and p53 Expression in Adult Mice. <i>Biomolecules</i> , 2022, 12, 532.	4.0	1
3	In vivo organized neovascularization induced by 3D bioprinted endothelial-derived extracellular vesicles. <i>Biofabrication</i> , 2021, 13, 035014.	7.1	21
4	Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties. <i>Cell Death and Disease</i> , 2021, 12, 558.	6.3	7
5	Role of Sex in the Therapeutic Targeting of p53 Circuitry. <i>Frontiers in Oncology</i> , 2021, 11, 698946.	2.8	3
6	p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With Thyroid Cancer and Autoimmunity. <i>Frontiers in Immunology</i> , 2021, 12, 728381.	4.8	5
7	Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas. <i>Thyroid</i> , 2020, 30, 290-299.	4.5	11
8	Sempervirine inhibits RNA polymerase I transcription independently from p53 in tumor cells. <i>Cell Death Discovery</i> , 2020, 6, 111.	4.7	10
9	Effect of p53 activation through targeting MDM2/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients. <i>PLoS ONE</i> , 2020, 15, e0228296.	2.5	10
10	Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4. <i>Cancers</i> , 2019, 11, 1349.	3.7	5
11	The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1 $\alpha$ Levels and Colorectal Cancer Cell Survival under Hypoxia. <i>Cell Reports</i> , 2017, 18, 1699-1712.	6.4	88
12	MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. <i>Molecular Cancer</i> , 2017, 16, 55.	19.2	12
13	Estrogens as a potential disease modifier in FSHD: a retrospective clinical study. <i>Neuromuscular Disorders</i> , 2017, 27, S200.	0.6	3
14	Intake of Boron, Cadmium, and Molybdenum enhances rat thyroid cell transformation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 73.	8.6	15
15	Association of TrkA and APP Is Promoted by NGF and Reduced by Cell Death-Promoting Agents. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 15.	2.9	19
16	Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity. <i>Journal of Clinical Investigation</i> , 2017, 127, 1531-1545.	8.2	46
17	MDM2&ndash;MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4221-4229.	6.7	11
18	Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 1417-1429.	5.0	14

#	ARTICLE	IF	CITATIONS
19	Allele-specific DNA hypomethylation characterises FSHD1 and FSHD2. <i>Journal of Medical Genetics</i> , 2016, 53, 348-355.	3.2	54
20	Novel insights about the MDM2/MDM4 heterodimer. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1066923.	0.7	3
21	MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. <i>Oncogene</i> , 2016, 35, 228-240.	5.9	33
22	The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 87.	8.6	24
23	Che-1 modulates the decision between cell cycle arrest and apoptosis by its binding to p53. <i>Cell Death and Disease</i> , 2015, 6, e1764-e1764.	6.3	35
24	Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy. <i>Cancer Research</i> , 2015, 75, 4560-4572.	0.9	38
25	MDM Genes. , 2014, , 2684-2689.		0
26	MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage. <i>Cell Cycle</i> , 2012, 11, 749-760.	2.6	20
27	IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1247-1256.	4.1	20
28	Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4). <i>MedChemComm</i> , 2011, 2, 455.	3.4	15
29	Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon?. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 287-294.	5.0	8
30	Maternal thyroid hormones are transcriptionally active during embryoâ€œfoetal development: results from a novel transgenic mouse model. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2417-2435.	3.6	20
31	Regulation of MDM4 (MDMX) function by p76MDM2: a new facet in the control of p53 activity. <i>Oncogene</i> , 2010, 29, 5935-5945.	5.9	14
32	Puzzling over MDM4â€™s p53 network. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1080-1083.	2.8	26
33	Mitochondrial MDM4 (MDMX): An unpredicted role in the p53-mediated intrinsic apoptotic pathway. <i>Cell Cycle</i> , 2009, 8, 3854-3859.	2.6	41
34	MDM4 (MDMX) and its Transcript Variants. <i>Current Genomics</i> , 2009, 10, 42-50.	1.6	37
35	MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. <i>EMBO Journal</i> , 2009, 28, 1926-1939.	7.8	75
36	Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. <i>Journal of Molecular Medicine</i> , 2008, 86, 585-596.	3.9	46

#	ARTICLE	IF	CITATIONS
37	Estrogen Receptor- $\beta$ and Endothelial Nitric Oxide Synthase Nuclear Complex Regulates Transcription of Human Telomerase. <i>Circulation Research</i> , 2008, 103, 34-42.	4.5	81
38	MDM2-Regulated Degradation of HIPK2 Prevents p53Ser46 Phosphorylation and DNA Damage-Induced Apoptosis. <i>Molecular Cell</i> , 2007, 25, 739-750.	9.7	161
39	Physicochemical and biological study of selected hydrophobic polyethylenimine-based polycationic liposomes and their complexes with DNA. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 1504-1515.	3.0	62
40	Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer. <i>Molecular Cancer Research</i> , 2006, 4, 79-92.	3.4	96
41	Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. <i>Cancer Gene Therapy</i> , 2005, 12, 381-388.	4.6	8
42	Telomerase Mediates Vascular Endothelial Growth Factor-dependent Responsiveness in a Rat Model of Hind Limb Ischemia. <i>Journal of Biological Chemistry</i> , 2005, 280, 14790-14798.	3.4	76
43	Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization. <i>Cancer Research</i> , 2005, 65, 9687-9694.	0.9	53
44	MDM4 (MDMX) Overexpression Enhances Stabilization of Stress-induced p53 and Promotes Apoptosis. <i>Journal of Biological Chemistry</i> , 2004, 279, 8169-8180.	3.4	35
45	MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. <i>Oncogene</i> , 2002, 21, 867-877.	5.9	36
46	Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. <i>Journal of Clinical Investigation</i> , 2002, 110, 219-227.	8.2	74
47	Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. <i>Journal of Clinical Investigation</i> , 2002, 110, 219-227.	8.2	15
48	Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. <i>Journal of Clinical Investigation</i> , 2002, 110, 219-227.	8.2	44
49	Inhibition of ER $\beta$ -Mediated Trans-Activation of Human Coagulation Factor XII Gene by Heteromeric Transcription Factor NF- $\kappa$ B. <i>Endocrinology</i> , 2001, 142, 3380-3388.	2.8	18
50	Inhibition of ER $\alpha$ -Mediated Trans-Activation of Human Coagulation Factor XII Gene by Heteromeric Transcription Factor NF- $\kappa$ B. <i>Endocrinology</i> , 2001, 142, 3380-3388.	2.8	6
51	Molecular pathogenesis of thyroid nodules and cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2000, 14, 517-539.	4.7	48
52	Effects of Exogenous p53 Transduction in Thyroid Tumor Cells with Different p53 Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 302-308.	3.6	19
53	Combined Impairment of Nutritional Parameters and Thyroid Homeostasis in Mildly Iodine-Deficient Children. <i>Thyroid</i> , 1998, 8, 155-159.	4.5	17
54	Orphan Receptor Hepatocyte Nuclear Factor-4 Antagonizes Estrogen Receptor $\alpha$ -Mediated Induction of Human Coagulation Factor XII Gene. <i>Endocrinology</i> , 1998, 139, 4581-4589.	2.8	13

#	ARTICLE	IF	CITATIONS
55	p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. <i>Oncogene</i> , 1997, 14, 729-740.	5.9	141
56	Rapid and sensitive high-performance liquid chromatographic method for the analysis of tryptophan, tyrosine and phenylalanine in biological samples. <i>Journal of Chromatography A</i> , 1991, 553, 149-154.	3.7	3
57	Non-ketotic hyperglycinaemia: a new case with late onset. <i>Journal of Inherited Metabolic Disease</i> , 1990, 13, 238-238.	3.6	1
58	Simultaneous high-performance liquid chromatographic determination of amino acids in a dried blood spot as a neonatal screening test. <i>Journal of Chromatography A</i> , 1990, 511, 131-136.	3.7	16
59	Rapid and sensitive method for high-performance liquid chromatographic analysis of pterins in biological fluids. <i>Journal of Chromatography A</i> , 1988, 459, 319-324.	3.7	14